meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
1
mEC - 1st line (L1)
1
mEC - 2nd line (L2)
3
gastric or gastroesophageal junction cancer (GC)
immune chekpoint inhibitors
anti-PD-(L)1
camrelizumab based treatment
camrelizumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
versus all
vs chemotherapy
vs Standard of Care (SoC)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab alone
title
Standard of Care (SoC)
title
KEYNOTE-181, 2020 NCT02564263 mEC - 2nd line (L2) 314/314
Pathology:
mEC - 2nd line (L2);
mEC - 2nd line (L2)
KEYNOTE-181, 2020
pembrolizumab alone
1
T1
Standard of Care (SoC)
0
T0